Bevacizumab combination therapy: For the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer

Drugs

Volumn 72, Issue 7, 2012, Pages 917-930

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Bevacizumab; Carboplatin; Fallopian tube cancer; Ovarian cancer; Paclitaxel; Peritoneal cancer; Pharmacoeconomics; Pharmacokinetics; Pharmacology

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; PACLITAXEL;

ABDOMINAL PAIN; ADVANCED CANCER; ASTHENIA; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; EPITHELIUM TUMOR; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; IN VITRO STUDY; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIMARY TUMOR; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR XENOGRAFT; UTERINE TUBE CARCINOMA; VOMITING; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860724862     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208940-000000000-00000     Document Type: Review

References (48)

1. Jemal A, Bray F, CenterMM, et al. Global cancer statistics. CA Cancer J Clin 2011 Mar 30; 61 (2): 69-90
2. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v23-30
3. Vaughan S, Coward JI, Bast RCJ, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 Oct; 11 (10): 719-25
4. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25 (20): 2902-8
5. Ledermann JA, Marth C, Carey MS, et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer 2011; 21 (4): 763-70
6. Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011 Jan; 18 (1): 31-43
7. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008 May 8; 358 (19): 2039-49
8. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999 Jan 1; 85 (1): 178-87
9. Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol 2004 Oct; 95 (1): 16-22
10. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003 Sep; 39 (13): 1948-56
11. Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer.GynecolOncol 2003Dec; 91 (3): 513-7
12. European Medicines Agency. Avastin (bevacizumab): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000582/WC 500029271.pdf [Accessed 2012 Jan 12]
13. European MedicinesAgency. Avastin (bevacizumab): summary of opinion, post authorisation (EMA/CHMP/569545/2011) [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/ 000582/WC500112811.pdf [Accessed 2011 Nov 18]
14. Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 2006; 5 (1): 43-60
15. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007; 67 (12): 1793-9
16. Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011 Nov 12; 71 (16): 2213-29
17. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005 Feb 1; 65 (3): 671-80
18. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7 (4): 335-45
19. Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14 (23): 7781-9
20. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006 Feb 10; 24 (5): 769-77
21. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19 (3): 843-50
22. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19 (3): 851-6
23. Hsei V, Deguzman GG, Nixon A, et al. Complexation of VEGF with bevaczumab decreases VEGF clearance in rats. Pharm Res 2002; 19 (11): 1753-6
24. Mabuchi S, Kawase C, Altomare DA, et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 2010 Aug; 9 (8): 2411-22
25. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57 (20): 4593-9
26. Yanagisawa M, Yorozu K, Kurasawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 2010; 21 (7): 687-94
27. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362 (6423): 841-4
28. Hu L, Hofmann J, Zaloudek C, et al. Vascular endothelial growth factor immunoneutralization plus paclitaxelmarkedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002 Nov; 161 (5): 1917-24
29. Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008 Apr; 6 (4): 525-34
30. Smerdel MP, Steffensen KD, Waldstrom M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010; 118 (2): 167-71
31. Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010; 119 (3): 484-90
32. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117 (3): 497-504
33. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010 May; 11 (5): 465-75
34. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009 Mar; 43 (3): 490-501
35. Wu JY, Wu XN, Ding L, et al. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer. Chin Med J 2010; 123 (7): 901-6
36. EuropeanMedicinesAgency. Avastin: European public assessment report: scientific discussion [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000582/WC 500029262.pdf [Accessed 2011 Nov 29]
37. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 Dec 29; 365 (26): 2473-83
38. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer.NEngl J Med 2011 Dec 29; 365 (26): 2484-96
39. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007; 17 (4): 771-6
40. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mü llerian tumors. J Clin Oncol 2010; 28 (1): 154-9
41. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001 Mar 15; 19 (6): 1809-17
42. Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003 Jul; 39 (10): 1402-8
43. Burger R, Brady M, Bookman M, et al. Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study [abstract no. 7]. Gynecol Oncol 2011; 120 Suppl. 1: S5
44. Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A costeffectiveness analysis. J Clin Oncol 2011; 29 (10): 1247-51
45. Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19 (2): 92-109
46. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006; 11 (2): 90-5
47. Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011; 21 (4): 756-62
48. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract]. J Clin Oncol 2011; 29 (15 Suppl.)